Citations

Clear

6273 citation(s) found for "To, Andrew".

Celebrating neuropathology's contributions to Alzheimer's Disease Research Centers
Fischer, D. Luke , Beach, Thomas G., Bieniek, Kevin F. , Chkheidze, Rati , Cohen, Mark L. , Crary, John F. , Dugger, Brittany N. , Dunlop, Sara , Haeri, Mohammad , Harrison, William , Head, Elizabeth, Hiniker, Annie , Huang, Eric J. , Kofler, Julia , Latimer, Caitlin S. , McKee, Ann C. , Mente, Karin , Miller, Michael B. , Montine, Thomas J., Nelson, Peter T. , Newell, Kathy L. , Perrin, Richard J., Ramani, Biswarathan , Reichard, R. Ross , Roy, Subhojit , Schlachetzki, Johannes C. M. , Wısnıewskı, Thomas , Lee, Edward B. , Head, Elizabeth , Dunlop, Sara R, Dugger, Brittany N , Lee, Edward B , Head, Elizabeth , Grinberg, Lea T. , Ahrendsen, Jared T. , Beach, Thomas G., Castellani, Rudolph J. , Cobos, Inma , Dickson, Dennis W. , Farrell, Kurt , Ghetti, Bernardino , Hüttner, Anita , Jamshidi, Pouya , Kapasi, Alifiya , Keene, C. Dirk , Miller, Michael B., Montine, Thomas J., Morris, Meaghan , Murray, Melissa E. , Seeley, William W. , Serrano, Geidy E. , Spina, Salvatore , Teich, Andrew F. , Wang, Shih‐Hsiu J.

Mayo Clinic

Alzheimer's & Dementia | October 14, 2025 | Volume: 21 | Issue: 10 | Pages: No page available

10.1002/alz.70734 | PMID 41085158 Get It

Abstract Our understanding of Alzheimer's disease (AD) and related dementias (ADRD) has grown exponentially, thanks to significant investments by the National Institute on Aging (NIA). This article celebrates the 40th anniversary of the NIA's Alzheimer's Disease Research Centers, highlighting the pivotal role of neuropathology as the bedrock for neurodegeneration research. Neuropathology has championed the key principles of proteinopathy, selective vulnerability, and stereotypic spread. Furthermore, neuropathologic studies advanced our understanding of ADRD prevalence, heterogeneity, clinical–pathological correlations, and genetic underpinnings, spurring biomarker development for target engagement and disease monitoring. Disease‐modifying therapies for AD were inspired and informed by neuropathology. The neuropathology community is poised to refine diagnostics, leveraging digital pathology and integrating genetics and pathomics to enhance subtyping for novel precision medicine approaches. Despite some common misconceptions and logistical challenges, neuropathology continues to be a critical component of the ADRD research infrastructure, serving as a key bridge between allied basic and clinical sciences. Highlights We celebrate 40 years of NIA‐funded ADRCs and their contributions through neuropathology studies that have significantly advanced our understanding and treatment of ADRD. Neuropathology uncovers principles of neurodegenerative disease: proteinopathy, selective vulnerability, and stereotypic spread, informing diagnostics and therapies. Development of AD biomarkers with reference to neuropathology enhances accuracy in diagnosis and monitoring, paving the way for targeted disease‐modifying therapies. Integration of digital pathology, genetics, and novel tools in neurodegeneration research promises advanced precision medicine approaches and refined diagnostics. Misconceptions and logistical challenges to neuropathological research are addressed to improve understanding and collaboration.
Intersurgeon Variability in Proptosis Reduction After Orbital Decompression for Thyroid Eye Disease: A Multicenter Analysis
Hong, Ashley, Shoji, Marissa K. , Villatoro, George A., Radha-Saseendrakumar, Bharanidharan, Dolman, Peter J. , Kazim, Michael, Harrison, Andrew R. , Lucarelli, Mark J., Garrity, James A., Selva, Dinesh , Ediriwickrema, Lilangi S. , Liu, Catherine Y., Korn, Bobby S. , Kikkawa, Don O. , Baxter, Sally L.

Mayo Clinic

Ophthalmic Plastic & Reconstructive Surgery | October 14, 2025 | Volume: 42 | Issue: 3 | Pages: 318-324

10.1097/iop.0000000000003090 | PMID 41082925 Get It

Purpose: This study assesses intersurgeon variability in proptosis reduction after orbital decompression for thyroid eye disease. Methods: This multicenter retrospective study included patients with thyroid eye disease who underwent orbital decompression from 1 of 7 surgeons at 7 different institutions between January 2002 and December 2018. Data were included if a single decompression technique was performed on ≥10 patients by ≥2 surgeons. The primary outcome was postoperative change in proptosis with emphasis on comparison among surgeons utilizing similar surgical techniques. Statistical analysis was performed with χ 2 and ANOVA testing, and a multivariable logistic regression model was generated. Results: Six hundred thirty-three orbits that underwent orbital decompression were included. Five different decompression techniques were analyzed: medial wall (n = 29), fat + lateral wall (n = 113), medial wall + floor (n = 123), fat + lateral wall + medial wall (n = 140), and fat + lateral wall + medial wall + floor (n = 228), without significant difference in proptosis reduction among surgeons. Surgeons did not demonstrate significant differences in outcomes at different time points compared with each other or themselves. Outcomes when comparing endoscopic versus open medial wall decompression varied among surgery types. Multivariate modeling revealed a statistically significant association between postoperative change in proptosis with preoperative proptosis ( p < 0.001). Conclusions: Postoperative change in proptosis did not differ significantly between surgeons utilizing similar orbital decompression techniques for patients with thyroid eye disease. This study may strengthen the statistical validity of multicenter clinical trials assessing orbital decompression outcomes performed by surgeons employing uniform surgical techniques, thereby advancing our understanding of optimal surgical management strategies for thyroid eye disease.
AMRrounds: Metallo-β-lactamase-producing Klebsiella pneumoniae complex—everything and the kitchen zinc
Dickinson, Drew T. , Ilges, Dan , Kobic, Emir , Bryan, Andrew , Bryan, Andrew , Ilges, Dan

Mayo Clinic

JAC-Antimicrobial Resistance | October 13, 2025 | Volume: 7 | Issue: 5 | Pages: No page available

10.1093/jacamr/dlaf187 | PMID 41089090 Get It

Rare but Relevant? Assessing Variants in Dystonia‐Linked Genes in Parkinson's Disease
Screven, Laurel A. , Tan, Ai Huey , Fenn, Matilda, Frost, Joshua L.I., Jankovic, Joseph, Jasaityte, Simona , Jeon, Beomseok , Sarmiento, Ignacio Juan Keller , Krüger, Rejko , Kuhlenbäumer, Gregor , Schirinzi, Tommaso , Shulman, Joshua M., Uitti, Ryan J. , Wu, Lesley , Zeuner, Kirsten E., Blauwendraat, Cornelis , Singleton, Andrew, Lohmann, Katja , (GP2), the Global Parkinson's Genetics Program, Tan, Ai Huey , Jeon, Beom Seok , Lin, Chin-Hsien , Schirinzi, Tommaso , Shin, Jung Hwan , Tay, Yi Wen , Uitti, Ryan, Warner, Thomas T. , Wszolek, Z.K. , Wu, Ruey-Meei , Blauwendraat, Cornelis , Morris, Huw R , Lohmann, Katja , Lange, Lara Mariah , Fang, Zih‐Hua , Alcalay, Roy N. , Amouri, Rim , Bovenzi, Roberta , Frost, Joshua L.I., Jankovic, Joseph J. , Jaunmuktane, Zane , Lin, Chin‐Hsien , Pavelka, Lukas , Periñán, María Teresa , Sassi, Samia Ben , Shulman, Joshua M. , Wszołek, Zbigniew K. , Wu, Ruey‐Meei , Singleton, Andrew , Mencacci, Niccolò Emanuele , Morris, Huw R. , Lim, Shen‐Yang , Klein, Christine , (GP2), the Global Parkinson's Genetics Program

Mayo Clinic

Movement Disorders | October 11, 2025 | Volume: 41 | Issue: 1 | Pages: 247-259

10.1002/mds.70073 | PMID 41074695 Get It

Abstract Background Dystonia and Parkinson's disease (PD) exhibit clinical and genetic overlap, but the relevance of dystonia gene variants in PD remains unclear. Objective The aim was to assess the frequency of dystonia‐linked pathogenic variants in PD. Methods We screened sequencing data from 15,684 individuals (8272 PD, 3200 atypical parkinsonism, and 4212 unaffected) from the Global Parkinson's Genetics Program (GP2) and Accelerating Medicines Partnership‐Parkinson's Disease (AMP‐PD) for variants in genes linked to isolated dystonia, dystonia‐parkinsonism, and myoclonus‐dystonia. Results Pathogenic variants were identified only in PD patients. Forty‐five PD individuals (0.54%) carried 26 distinct (likely) pathogenic variants in nine dystonia‐linked genes, most frequently in GCH1 , followed by VPS16 . Conclusion Though rare, pathogenic variants in dystonia‐linked genes are present in clinically and pathologically diagnosed PD. Our results reinforce GCH1 as a PD‐relevant gene with clinical implications, whereas variants identified in other genes are rare and of uncertain relation to the PD phenotype. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Incidence of chronic medical conditions among survivors of adolescent and young adult cancer compared to a population without cancer
Keegan, Theresa H.M. , Abrahão, Renata , Chubak, Jessica , Sauder, Candice A. M. , Ruddy, Kathryn J. , Li, Qian , Haupt, Eric C. , Laurent, Cecile A. , Casperson, Mallory, Chao, Chun , Smitherman, Andrew B. , Nichols, Hazel B. , Chao, Chun , Smitherman, Andrew B , Nichols, Hazel B , Hahn, Erin E , Chubak, Jessica , Quesenberry, Charles P. , Li, Qian , Brunson, Ann , Kirchhoff, Anne C. , Kushi, Lawrence H.

Mayo Clinic

Cancer | October 10, 2025 | Volume: 131 | Issue: 20 | Pages: No page available

10.1002/cncr.70125 | PMID 41070762 Get It

Abstract Background Few studies have assessed the burden of chronic medical conditions in adolescent and young adult (AYA) cancer survivors. This study estimated the risk of these conditions among AYA survivors compared to a matched cohort without cancer. Methods This retrospective cohort study included 2‐year survivors ( n = 14,917) of 11 common AYA (15–39 years) cancers diagnosed at the integrated health care organizations of Kaiser Permanente (KP) Southern and Northern California during 2006–2020. A comparison cohort ( n = 149,164) without cancer (matched 10:1 by age, sex, calendar year, and KP site) was included. Cumulative incidence (CMI) accounting for death as a competing risk was calculated. Poisson regression estimated the incidence rate ratio (IRR) of each condition in cancer survivors versus the matched cohort, adjusting for age, sex, and race/ethnicity. Results The 5‐year CMI was highest for thyroid (17.4%), respiratory (6.6%), cardiovascular (5.0%), and liver (4.8%) diseases. At 10 years, the CMI of any condition was 39% in survivors versus 26% in the matched cohort. Survivors had a 2‐fold increased risk of being diagnosed with any medical condition (IRR, 2.0; 95% confidence interval [CI], 1.9–2.0) as well as two or more conditions (IRR, 2.3; 95% CI, 2.2–2.5). Risk was highest among survivors of hematologic cancers and those diagnosed with distant stage disease. Elevated risks were observed within all sociodemographic groups of this insured population. Conclusion AYAs with cancer had a higher risk of chronic medical conditions compared to those without cancer. Long‐term surveillance, risk mitigation through lifestyle modifications and effective disease management are crucial to reduce premature mortality.
NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025
Advani, Ranjana H. , Andreadis, B., Chang, Julie , Christian, Beth , deVos, Sven, Fayad, Luis , Hamid, Muhammad Saad , Hernandez‐Ilizaliturri, Francisco J. , Karimi, Yasmin , King, Rebecca L. , Krivacic, Susan, LaCasce, Ann S. , Messmer, Marcus , Rabinovitch, Rachel , Roberts, Kenneth B. , Saito, Naoyuki G. , Smith, Stephen D. , Swinnen, Lode J., Tuscano, Joseph M. , Dwyer, Mary A., Sundar, Hema, Advani, Ranjana H , Karimi, Yasmin H , Zelenetz, Andrew D. , Gordon, Leo I. , Abramson, Jeremy S. , Bartlett, Nancy L. , Budde, Lihua E. , Caimi, Paolo F. , Dholaria, Bhagirathbhai , Habermann, Thomas M. , Hu, Boyu , Kelsey, Chris R. , Kline, Justin Paul , Landsburg, Daniel J. , Lim, Megan S. , Ramakrishnan, Praveen , Reid, Erin G , Saeed, Hayder , Vose, Julie M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 9, 2025 | Volume: 23 | Issue: 10 | Pages: No page available

10.6004/jnccn.2025.0048 | PMID 41067277 Get It

The treatment landscape of B-cell lymphomas has significantly evolved in recent years with approval of novel targeted therapies. CD3 × CD20 bispecific antibodies and CD19-directed monoclonal antibodies and antibody–drug conjugates have demonstrated efficacy in relapsed/refractory follicular lymphoma (FL). Bruton tyrosine kinase (BTK) inhibitor–based regimens are emerging as effective treatment options for patients with TP53-mutated classical mantle cell lymphoma (MCL). Results from ongoing clinical trials suggest that the addition of CD3 × CD20 bispecific antibodies to chemoimmunotherapy improves outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). These NCCN Guideline Insights highlight significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, MCL, and DLBCL.
Genomics Define Malignant Transformation in Myeloma Precursor Conditions
Maura, Francesco , Bergsagel, P. Leif , Kumar, Shaji , Maclachlan, Kylee , Derkach, Andriy , Garcés, Juan‐José , Firestone, Ross , Braggio, Esteban , Asmann, Yan W. , Papadimitriou, Marios , Hultcrantz, Malin , Marella, Alessio , Castellano, Giancarlo , Lionetti, Marta , Matera, Antonio , Pioggia, Stefania, Vià, Matteo Da , Magistris, Claudio De, Siegel, Erin M. , Agius, Phaedra , Teer, Jamie K. , Yamashita, Yusuke , Silva, Ariosto S. , Blaney, Patrick , Patel, Krina K. , Campbell, Peter J. , Morgan, Gareth , Orlowski, Robert Z. , Shain, Kenneth H. , Bolli, Niccolò , Bergsagel, P. Leif , Kumar, Shaji K , Maclachlan, Kylee , Derkach, Andriy , Garces, Juan-Jose , Firestone, Ross , Braggio, Esteban , Asmann, Yan, Durante, Michael , Diamond, Benjamin T , Hultcrantz, Malin , Marella, Alessio , Castellano, Giancarlo , Maeda, Akihiro , Lionetti, Marta , Matera, Antonio , Da Vià, Matteo C , de Magistris, Claudio , DeAvila, Danny , Sudalagunta, Praneeth Reddy , Canevarolo, Rafael Renatino , Siegel, Erin M , Teer, Jamie K , McPherson, Andrew , Yamashita, Yusuke , Blaney, Patrick , Baz, Rachid , Patel, Krina , Fonseca, Rafael , Landgren, C Ola , Orlowski, Robert Z. , Shain, Kenneth H , Bolli, Niccolo' , Usmani, Saad , Rajkumar, S Vincent , Maura, Francesco , Ziccheddu, Bachisio , Durante, Michael , Diamond, Benjamin , Leongamornlert, Daniel , Fonseca, Rafaël , Landgren, Ola , Usmani, Saad Z. , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | October 8, 2025 | Volume: 44 | Issue: 3 | Pages: 188-199

10.1200/jco-25-01733 | PMID 41061199 Get It

Multiple myeloma (MM) is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). While these precursor conditions are asymptomatic, they are not entirely benign and carry a lifelong risk of progression to MM. Unlike other cancers defined by pathology, malignant transformation from MGUS or SMM to MM has so far relied on demonstration of clinical end-organ damage as morphology and cytogenetics cannot reliably distinguish them. In this study, using genomic data from 374 patients with MGUS or SMM (277 training, 97 validation), to our knowledge, we demonstrate for the first time the ability to identify malignant transformation in MGUS and SMM. We introduce the concept of genomic MM and genomic MGUS to differentiate the subsets of MGUS and SMM that are biologically malignant with genomic features indistinguishable from MM from the subset that is premalignant and unlikely to progress to malignancy. Importantly, we find that most SMM has biological features of malignant transformation indistinguishable from MM. As expected, this subset that we consider having genomic MM is associated with a high risk of progression to MM although some patients remained progression-free beyond 5 years. Conversely, 60% of MGUS and 10% of SMM have no evidence of malignant transformation (genomic MGUS), with no progression during follow-up. Integration of genomic features with the 2/20/20 International Myeloma Working Group model significantly improved the prediction of progression among genomic MM. These findings support the use of genomic criteria to refine the classification and the risk stratification in myeloma precursor conditions.
Voice and Choice: Voice Equivalence and Representational Choice in Virtual Health Assistants for Colorectal Cancer Screening Among Black American Adults
Maxim, Andrew , Cooks, Eric , Krieger, Janice L. , Lok, Benjamin

Mayo Clinic

Proceedings of the 25th ACM International Conference on Intelligent Virtual Agents | October 8, 2025 | Volume: No volume available | Issue: No issue available | Pages: 1-10

10.1145/3717511.3747065 | PMID 42898760 Get It